Synthesis and in Vitro Evaluation of New Nitro-Substituted Thiazolyl Hydrazone Derivatives as Anticandidal and Anticancer Agents

Abstract

Fourteen new thiazolyl hydrazone derivatives were synthesized and evaluated for their anticandidal activity using a broth microdilution assay. Among the synthesized compounds, 2-[2-((5-(4-chloro-2-nitrophenyl) furan-2-yl) methylene) hydrazinyl]-4-(4-fluorophenyl) thiazole and 2-[2-((5-(4-chloro-2-nitrophenyl) furan-2-yl) methylene) hydrazinyl]-4-(4-methoxyphenyl) thiazole were found to be the most effective antifungal compounds against Candida utilis, with a MIC value of 250 mu g/mL, when compared with fluconazole (MIC = 2 mu g/mL). Additionally, the synthesized compounds were evaluated for their in vitro cytotoxic effects on the MCF-7 and NIH/3T3 cell lines. As a result, 2-[2-((5-(4-chloro-2-nitrophenyl) furan-2-yl) methylene) hydrazinyl]-4-(4-chlorophenyl) thiazole was identified as the most promising anticancer compound against MCF-7 cancer cells due to its inhibitory effects (IC50 = 125 mu g/mL) and relatively low toxicity towards the NIH/3T3 cell line (IC50 > 500 mu g/mL).